What are the precautions for taking datopotomab?

Datopotamab Deruxtecan (Dato-DXd for short) is an antibody drug conjugate (ADC) used to treat multiple types of cancer, including metastatic triple-negative breast cancer (TNBC) and other solid tumors. Although dabrotomab has shown good clinical efficacy, some key matters need to be paid attention to during use to ensure the safety and effectiveness of the treatment. The following are things that patients need to pay special attention to when using dabrotuzumab:

1. Allergic reactions and injection-related reactions

Dabrotuzumab is given as an intravenous infusion and may cause allergic reactions or injection-related reactions. Common adverse reactions include rash, fever, chills, shortness of breath, facial swelling and chest pain. Patients need to report to their doctor if they have any history of drug allergy or allergy to other biological agents before receiving dabrotomab injection. If allergic symptoms occur during or after the injection, the patient should inform the doctor or nurse immediately. To avoid allergic reactions, treatment may require pretreatment medications, such as anti-allergic and anti-inflammatory drugs, to reduce the occurrence of reactions.

2. Glioma-like reaction and pulmonary toxicity

Dedabrotuzumab may cause adverse pulmonary reactions, such as pneumonia, interstitial lung disease (ILD), etc. Pulmonary toxicity is one of the more serious side effects of dedabrotumumab treatment, which may lead to symptoms such as dyspnea, persistent cough, and chest pain. Patients will need regular pulmonary monitoring while using this drug, especially early in treatment or when the dose is increased. If you develop lung symptoms such as cough, difficulty breathing or chest pain, you should inform your doctor immediately. Treatment may need to be suspended and necessary examinations and treatments performed. If pulmonary adverse effects are treated promptly, patient prognosis is usually good.

3. Other common side effects

In addition to allergic reactions and pulmonary toxicity, dabrotuzumab may cause other adverse reactions, including gastrointestinal symptoms (such as nausea, vomiting, diarrhea), hematological abnormalities (such as anemia, leukopenia), and neurological symptoms (such as headache, dizziness, etc.). Therefore, during the use of dabrotuzumab, patients need to undergo regular physical examinations, including blood routine, liver and kidney function tests, etc., to monitor potential side effects. Once symptoms of discomfort are discovered, patients should report to the doctor promptly so that the treatment plan can be adjusted.

4. Taboos during pregnancy and lactation

Dabrotuzumab is a biologic agent that may cause adverse effects on the fetus and infant. Dedabrotuzumab should be avoided in pregnant or breastfeeding women. Drugs may cause harm to the fetus, so female patients need to undergo a pregnancy test before treatment and ensure that effective contraceptive measures are used during treatment. If the patient is breastfeeding, it is recommended to discontinue breastfeeding and consider alternative feeding methods. If you become pregnant or plan to become pregnant during use, you should stop taking the medicine immediately and discuss the risks of treatment with your doctor.

5. Other drug interactions

Dabrotuzumab may interact with other drugs, affecting the metabolism and effectiveness of the drugs. Patients should inform their doctor about any other medications they are taking while taking dabrotuzumab, including prescription drugs, over-the-counter drugs, herbal remedies, and supplements. This is especially true for drugs that may affect hepatic enzymes (CYP450), as the metabolism of dabrotuzumab may be affected by these drugs. Depending on the patient's specific condition, the doctor may need to adjust the dosage or substitute the medication.

6. Liver function monitoring

During treatment, the patient's liver function also needs to be closely monitored. Dabrotuzumab may cause liver damage, manifested by symptoms such as elevated liver enzymes. If abnormal liver function indicators occur, treatment should be suspended and evaluated. After liver function returns to normal, doctors may restart treatment based on the patient's specific circumstances.

7. Monitoring and follow-up during use

Patients taking dabrotuzumab should undergo regular physical examinations and follow-up visits, including monitoring white blood cell count, hemoglobin levels, liver and kidney function, etc. This helps to detect potential side effects early and ensures patient efficacy and safety. Patients should strictly follow the doctor's instructions, conduct treatment according to the prescribed dosage and course of treatment, and avoid stopping the medication or changing the dosage on their own.

In short, although dabrotuzumab has significant efficacy in the treatment of metastatic breast cancer and other tumors, there are some matters that require special attention during its use. Patients should undergo treatment under the guidance of a doctor, pay close attention to side effects during treatment, and make timely adjustments and management to ensure the safety and effectiveness of treatment.

Reference: https://clinicaltrials.gov/